SKC's AMNOG orphan tracker records the most important changes to all orphan drug procedures during and after the AMNOG for an efficient overview on a bimonthly basis.
The AMNOG orphan tracker provides all essential information about
- New AMNOG orphan drug procedures (active ingredient, trade name, reason for submission, indication)
- Completed AMNOG orphan drug procedures (active ingredient, trade name, indication, highest additional benefit) and
- New rebates for AMNOG orphan drug procedures (active ingredient, trade name, indication, highest added benefit, negotiated rebate)
The SKC Insights offer you further details on exciting AMNOG analyses.
The analyses are generated by data from SKC's proprietary MAIS database.
Download
Here you can download all issues of the AMNOG orphan tracker free of charge.
AMNOG orphan tracker March / April 2023
ATMPs are becoming ever more present: A new ATMP procedure has been launched with Ebvallo®. Furthermore Roctavian® and Tecartus® were both given a non-quantifiable additional benefit and a reimbursement amount was set for Abecma®.
PDF 139 kB Download
Full Market Access
Hands-on support throughout the whole process: from strategic positioning all the way to price negotiation, we accompany you seamlessly.
to the top